247 related articles for article (PubMed ID: 22628425)
21. Quality Control and Validation Issues in LC-MS Metabolomics.
Begou O; Gika HG; Theodoridis GA; Wilson ID
Methods Mol Biol; 2018; 1738():15-26. PubMed ID: 29654580
[TBL] [Abstract][Full Text] [Related]
22. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
23. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
25. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
26. Identification of key metabolites during cisplatin-induced acute kidney injury using an HPLC-TOF/MS-based non-targeted urine and kidney metabolomics approach in rats.
Qu X; Gao H; Sun J; Tao L; Zhang Y; Zhai J; Song Y; Hu T; Li Z
Toxicology; 2020 Feb; 431():152366. PubMed ID: 31926187
[TBL] [Abstract][Full Text] [Related]
27. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
28. Blood- and Urine-Based Liquid Biopsy for Early-Stage Cancer Investigation: Taken Clear Renal Cell Carcinoma as a Model.
Liu X; Zhang M; Shao C; Sun H; Zhang B; Guo Z; Sun J; Qi F; Zhang Y; Niu H; Sun W
Mol Cell Proteomics; 2023 Aug; 22(8):100603. PubMed ID: 37348606
[TBL] [Abstract][Full Text] [Related]
29. Urinary acylcarnitines are altered in human kidney cancer.
Ganti S; Taylor SL; Kim K; Hoppel CL; Guo L; Yang J; Evans C; Weiss RH
Int J Cancer; 2012 Jun; 130(12):2791-800. PubMed ID: 21732340
[TBL] [Abstract][Full Text] [Related]
30. Development of chemical isotope labeling liquid chromatography mass spectrometry for silkworm hemolymph metabolomics.
Shen W; Han W; Li Y; Meng Z; Cai L; Li L
Anal Chim Acta; 2016 Oct; 942():1-11. PubMed ID: 27720112
[TBL] [Abstract][Full Text] [Related]
31. Biotransformation-based metabolomics profiling method for determining and quantitating cancer-related metabolites.
Yue X; He J; Zhang R; Xu J; Zhou Z; Zhang R; Bi N; Wang Z; Sun C; Wang L; Chen Y; Abliz Z
J Chromatogr A; 2018 Dec; 1580():80-89. PubMed ID: 30473010
[TBL] [Abstract][Full Text] [Related]
32. STRATEGIES AND CHALLENGES IN METHOD DEVELOPMENT AND VALIDATION FOR THE ABSOLUTE QUANTIFICATION OF ENDOGENOUS BIOMARKER METABOLITES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY.
Khamis MM; Adamko DJ; El-Aneed A
Mass Spectrom Rev; 2021 Jan; 40(1):31-52. PubMed ID: 31617245
[TBL] [Abstract][Full Text] [Related]
33. Metabolomic Analysis Using Liquid Chromatography/Mass Spectrometry for Gastric Cancer.
Liang Q; Wang C; Li B
Appl Biochem Biotechnol; 2015 Aug; 176(8):2170-84. PubMed ID: 26088916
[TBL] [Abstract][Full Text] [Related]
34. Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics.
Shao CH; Chen CL; Lin JY; Chen CJ; Fu SH; Chen YT; Chang YS; Yu JS; Tsui KH; Juo CG; Wu KP
Oncotarget; 2017 Jun; 8(24):38802-38810. PubMed ID: 28415579
[TBL] [Abstract][Full Text] [Related]
35. GC-MS metabolomics-based approach for the identification of a potential VOC-biomarker panel in the urine of renal cell carcinoma patients.
Monteiro M; Moreira N; Pinto J; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Carvalho M; Guedes de Pinho P
J Cell Mol Med; 2017 Sep; 21(9):2092-2105. PubMed ID: 28378454
[TBL] [Abstract][Full Text] [Related]
36. Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens.
Prieto DA; Johann DJ; Wei BR; Ye X; Chan KC; Nissley DV; Simpson RM; Citrin DE; Mackall CL; Linehan WM; Blonder J
Biomark Med; 2014; 8(2):269-86. PubMed ID: 24521024
[TBL] [Abstract][Full Text] [Related]
37. Targeted metabolomics: Liquid chromatography coupled to mass spectrometry method development and validation for the identification and quantitation of modified nucleosides as putative cancer biomarkers.
Godoy AT; Eberlin MN; Simionato AVC
Talanta; 2020 Apr; 210():120640. PubMed ID: 31987192
[TBL] [Abstract][Full Text] [Related]
38. Urine metabolomic analysis in clear cell and papillary renal cell carcinoma: A pilot study.
Oto J; Fernández-Pardo Á; Roca M; Plana E; Solmoirago MJ; Sánchez-González JV; Vera-Donoso CD; Martínez-Sarmiento M; España F; Navarro S; Medina P
J Proteomics; 2020 Apr; 218():103723. PubMed ID: 32126320
[TBL] [Abstract][Full Text] [Related]
39. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes.
Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D
Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664
[TBL] [Abstract][Full Text] [Related]
40. Liquid chromatography-mass spectrometry untargeted metabolomics reveals increased levels of tryptophan indole metabolites in urine of metabolic syndrome patients.
Esperanza MG; Wrobel K; Ojeda AG; Garay-Sevilla ME; Escobosa ARC; Barrientos EY; Wrobel K
Eur J Mass Spectrom (Chichester); 2020 Dec; 26(6):379-387. PubMed ID: 33295818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
